Segment Information (Schedule of Segment Information) (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | $ 14,629,000 | $ 34,752,000 | $ 42,555,000 | $ 64,567,000 |
| Cost of goods - product revenue | (5,285,000) | (6,429,000) | (18,642,000) | (20,645,000) |
| Research and development | (9,446,000) | (20,348,000) | (46,941,000) | (91,995,000) |
| Selling, general and administrative | (21,993,000) | (21,733,000) | (60,867,000) | (71,512,000) |
| Asset impairment | (2,649,000) | (3,143,000) | ||
| Other income (expense) | (4,530,000) | 3,175,000 | (8,020,000) | (2,300,000) |
| Income Tax refund (expense) | (69,000) | (141,000) | 24,000 | (142,000) |
| Net loss | (26,694,000) | (10,724,000) | (94,540,000) | (125,170,000) |
| Dermatology Products Sales | ||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 14,629,000 | 34,539,000 | 42,514,000 | 63,924,000 |
| Cost of goods - product revenue | (5,285,000) | (6,429,000) | (18,642,000) | (20,645,000) |
| Research and development | (842,000) | (2,229,000) | (9,639,000) | (6,036,000) |
| Selling, general and administrative | (11,396,000) | (8,636,000) | (30,144,000) | (34,069,000) |
| Asset impairment | (3,143,000) | |||
| Other income (expense) | 504,000 | (361,000) | (282,000) | (1,646,000) |
| Income Tax refund (expense) | (95,000) | (95,000) | ||
| Net loss | (2,390,000) | 16,789,000 | (16,193,000) | (1,710,000) |
| Pharmaceutical and Biotechnology Product Development | ||||
| Segment Reporting Information [Line Items] | ||||
| Net Revenue | 213,000 | 41,000 | 643,000 | |
| Cost of goods - product revenue | 0 | |||
| Research and development | (8,604,000) | (18,119,000) | (37,302,000) | (85,959,000) |
| Selling, general and administrative | (10,597,000) | (13,097,000) | (30,723,000) | (37,443,000) |
| Asset impairment | (2,649,000) | |||
| Other income (expense) | (5,034,000) | 3,536,000 | (7,738,000) | (654,000) |
| Income Tax refund (expense) | (69,000) | (46,000) | 24,000 | (47,000) |
| Net loss | $ (24,304,000) | $ (27,513,000) | $ (78,347,000) | $ (123,460,000) |
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|